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ABSTRACT
Differences in cardiac and aortic structure and function are associated with cardiovascular diseases and a wide range of
other types of disease. Here we analyzed cardiovascular magnetic resonance images from a population-based study, the UK
Biobank, using an automated machine learning-based analysis pipeline. We report a comprehensive range of structural and
functional phenotypes for the heart and aorta across 26,893 participants and explore how these phenotypes vary according
to sex, age and major cardiovascular risk factors. We extended this analysis with a phenome-wide association study, in
which we tested for correlations of a wide range of non-imaging phenotypes of the participants with imaging phenotypes. We
further explored the associations of imaging phenotypes with early-life factors, mental health and cognitive function using both
observational analysis and Mendelian randomization. Our study illustrates how population-based cardiac and aortic imaging
phenotypes can be used to better define cardiovascular disease risks as well as heart-brain health interactions, highlighting
new opportunities for studying disease mechanisms and developing image-based biomarkers.
Cardiac and aortic structure and function are associated with cardiovascular diseases (CVDs)1, 2 and a wide range of other types
of disease3–6. Quantitative phenotypes derived from cardiovascular magnetic resonance (CMR) images enable us to assess
cardiac and aortic structure and function in a non-invasive way and provide important biomarkers for the determination of
pathological states in CVDs. For example, the left ventricular ejection fraction (LVEF) is an important clinical biomarker
for the diagnosis and treatment of heart failure1. The left ventricular myocardial mass (LVM) is widely used for classifying
hypertrophy and predicting risks of cardiovascular events7. Although CMR imaging phenotypes clearly play an important role
in disease research and diagnosis, extracting these phenotypes demand significant involvement of experienced image analysts.
This has become a limiting factor for applying CMR in large-scale studies and exploiting imaging phenotypes at a population
level.
Large-scale imaging studies potentially provide a wealth of information for investigating disease risk factors and discovering
early-stage image-based biomarkers. Recent large-scale imaging studies collecting CMR images include the Framingham Heart
Study (offspring cohort: 1,114 subjects)8, MESA (5,004 subjects)9, DETERMINE (655 subjects)10, Dallas Heart Project (2,921
subjects)11 and UK Digital Heart Project (∼2,000 subjects)12, to name a few. They illustrated the potential informativeness of
CMR in large-scale studies, but lacked the power to explore a wide range of individual phenotypes simultaneously.
UK Biobank is a population-based prospective study for investigating risk factors of common adult diseases in middle and
old age13–16. It recruited 500,000 women and men initially aged 40-69 years old between 2006-10 for long-term follow-up,
from whom extensive sociodemographic, life-style and health-related information were collected serially along with a range
of physical measurements and a growing range of genetic and biomarker data. Currently, UK Biobank is in the process of
acquiring comprehensive multi-modal images of different organ systems from 100,000 participants using a highly standardised
protocol, including magnetic resonance (MR) scans of the heart, brain and abdomen, ultrasound scans of carotid arteries, whole
body dual-energy X-ray absorptiometry (DXA) scan of bones and joints, retinal photographs and optical coherence tomography
(OCT) images14. These will add additional imaging phenotypes for understanding the determinants of diseases.
Deriving quantitative imaging phenotypes at this scale forms a major challenge. Recently, an image analysis pipeline has
been developed for UK Biobank brain MR images, which generates ∼4,350 imaging phenotypes of brain structure and function
for 10,000 subjects17. The derived brain imaging phenotypes, along with the breadth of life-style and health information
collected by UK Biobank, provide a valuable resource for studying the influence of ageing, progression of neuropathology and
identifying early-stage image-based biomarkers for diseases18. An initial genome-wide association study (GWAS) has been
performed19, which identified 148 clusters of associations between single nucleotide polymorphisms (SNPs) and brain imaging
phenotypes that replicate at p < 0.05, providing insights into the genetic architecture relevant to the brain.
Here we present cardiac and aortic structural and functional imaging phenotypes for 26,893 subjects and demonstrate
association studies enabled by these imaging phenotypes at a population level. The phenotypes were derived from UK Biobank
CMR images using an automated machine learning-based analysis pipeline, built upon previously proposed cardiac and
aortic image segmentation methods using convolutional neural networks20, 21. The pipeline evaluates comprehensive imaging
phenotypes for the heart and aorta, including global phenotypes of the four cardiac chambers and two aortic sections: the left
ventricle (LV), right ventricle (RV), left atrium (LA), right atrium (RA), ascending aorta (AAo) and descending aorta (DAo), as
well as regional phenotypes of the LV myocardial wall thickness and strain. We report associations of the cardiac and aortic
imaging phenotypes with sex, age and traditional cardiovascular risk factors. We then conducted a large, population-based
phenome-wide association study to relate the cardiac and aortic phenotypes to non-imaging phenotypes. We discovered a wide
range of highly significant associations with life style, early-life factors, mental health and cognitive function of the participants.
Anatomical structure Quantitative imaging phenotypes
Left ventricle (LV) End-diastolic volume, end-systolic volume, stroke volume, ejection fraction, cardiac
output, myocardial mass, global and regional myocardial wall thickness at end-diastole,
global and regional peak circumferential, radial and longitudinal strains
Right ventricle (RV) End-diastolic volume, end-systolic volume, stroke volume, ejection fraction
Left atrium (LA) Maximum volume, minimum volume, stroke volume, ejection fraction
Right atrium (RA) Maximum volume, minimum volume, stroke volume, ejection fraction
Ascending aorta (AAo) Maximum area, minimum area, aortic distensibility
Descending aorta (DAo) Maximum area, minimum area, aortic distensibility
Table 1. Quantitative imaging phenotypes of the heart and aorta, derived from short-axis, long-axis and aortic cine images.
Results
Image phenotyping
Figure 1 summarises the image analysis steps performed on short-axis, long-axis and aortic cine images (see detail in Methods).
In total, 82 quantitative imaging phenotypes characterising the structure and function of the heart and aorta (Table 1) were
generated for each subject. After running the analysis pipeline and performing quality control (Supplementary Table 1), imaging
phenotypes were available for 26,893 subjects. Supplementary Table 2 describes the basic participant characteristics of the
population. Supplementary Tables 3-6 report the summary statistics of the derived imaging phenotypes.
Associations with sex and age
We investigated imaging phenotypes which describe cardiac and aortic size (mass, volume or area) and change (ejection
fraction or distensibility) during a cardiac cycle. Two or three imaging phenotypes were selected for each of the six anatomical
structures, including the LV myocardial mass (LVM), LV end-diastolic volume (LVEDV), LV ejection fraction (LVEF), RV
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Figure 1. Automated CMR image analysis pipeline. a) LV and RV volumes are derived from short-axis image
segmentation (red: LV cavity; green: myocardium; blue: RV cavity). b, c) LA and RA volumes are derived from long-axis
image segmentation (purple: LA cavity; orange: RA cavity), as illustrated using a 4 chamber view (b) and a 2 chamber view (c).
d) AAo and DAo cross-sectional areas are derived from aortic image segmentation (red: AAo; green: DAo). e) Myocardial
wall thickness is measured using the distance between LV endocardial contour (red) and epicardial contour (green). f) For
measurement of myocardial wall thickness, three short-axis image slices are selected, including a basal slice at 25% of the LV
length (the distance from the mitral annular plane to the apex of the LV), a mid-cavity slice at 50% and an apical slice at 75% of
the LV length. The endocardial and epicardial contours are divided into 16 AHA segments, which are coded by different colors,
as indicated by the color bar. g) Motion tracking is performed on short-axis image slices, warping the contours to each time
frame across a cardiac cycle. Circumferential and radial strains (color-coded on the contours) are calculated using the change of
length of the line segments. h) On the long-axis 4 chamber view image, the endocardial and epicardial contours are divided
into 6 segments (coded by different colors). i) Motion tracking is performed on the long-axis 4 chamber view image.
Longitudinal strain is calculated using the change of length of the line segments.
end-diastolic volume (RVEDV), RV ejection fraction (RVEF), LA maximum volume (LAV max), LA ejection fraction (LAEF),
RA maximum volume (RAV max), RA ejection fraction (RAEF), AAo maximum area, AAo distensibility, DAo maximum area
and DAo distensibility.
We first characterised the associations of these phenotypes with sex and age in the population. Subjects with self-reported
CVDs were excluded to mitigate the impact of established cardiac conditions on imaging phenotypes. As the majority of the
subjects were Caucasian, we excluded other ethnicities to mitigate the impact of ethnicity. After these exclusions, 23,415
subjects were used with available sex and age information. Multiple linear regression models were built, using each imaging
phenotype as the dependent variable and sex and age as independent variables. An interaction term sex * age was included for
LVM, LVEDV, RVEDV, RAEF, AAo distensibility and DAo distensibility, where it led to a model of better fit (one-sided F-test,
p < 0.05).
Figure 2 and Supplementary Table 7 report the regression results. Overall, myocardial mass (LVM: β = 53.0, p = 3×10−218),
cardiac chamber volumes (LVEDV: β = 53.1, p = 2.9×10−74; RVEDV: β = 71.1, p = 7.7×10−116; LAV max: β = 10.6,
p = 2.6×10−297; RAV max: β = 22.7, p = 10−324) and aortic cross-sectional areas (AAo max area: β = 143.9, p = 10−324;
DAo max area: β = 104.9, p = 10−324) were greater for men than for women. Men consistently had lower cardiac chamber
ejection fractions (LVEF: β =−3.2, p = 10−324; RVEF: β =−4.1, p = 10−324; LAEF: β =−0.9, p = 1.7×10−15; RAEF:
β =−8.9, p = 1.4×10−19) than women.
In this cross-sectional study, ageing was associated with reduced myocardial mass and cardiac chamber volumes (LVM:
β =−1.0, p = 2.2×10−12; LVEDV: β =−5.9, p = 2.5×10−136; RVEDV: β =−6.1, p = 4.7×10−130; LAV max: β =−2.0,
p = 9.1×10−44; RAV max: β = −1.0, p = 1.7×10−9), increased aortic areas (AAo max area: β = 29.3, p = 6.1×10−146;
DAo max area: β = 20.8, p = 10−324) and reduced aortic distensibilities (AAo disten.: β =−0.7, p = 10−324; DAo disten.:
β =−0.8, p = 10−324). We found that women had greater aortic distensibilities than men between 40 to 50 years old (Figure 2).
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Figure 2. Associations of selected imaging phenotypes with sex and age. n = 23,415 subjects were used in analysis. Each
graph displays a kernel density plot of an imaging phenotype plotted against age, as well as the linear regression lines for the
whole population (gray), for women (red) and for men (blue). Detailed regression coefficients and association p-values can be
found in Supplementary Table 7.
However, there was a strong sex and age interaction (AAo disten.: β = 0.1, p = 8.4×10−14; DAo disten.: β = 0.1, p = 10−11).
Aortic distensibilities decreased more quickly with age for women than for men. LVM, LVEDV, RVEDV and RAEF also
exhibited strong sex and age interactions. Myocardial mass and ventricular volumes decreased more quickly with age for men
than for women (LVM: β =−2.4, p = 5.6×10−36; LVEDV: β =−1.5, p = 8.6×10−6; RVEDV: β =−2.6, p = 4.6×10−13).
Associations with traditional cardiovascular risk factors
We explored the associations of cardiac and aortic imaging phenotypes with demographics (sex, age, sex * age), anthropometrics
(weight, height) and cardiovascular risk factors22, including systolic blood pressure (SBP), diastolic blood pressure (DBP),
current smoking status, alcohol intake, vigorous physical activity (PA) frequency, high cholesterol and diabetes. Sex, current
smoking status, high cholesterol and diabetes are binary variables. The others are continuous variables.
Supplementary Table 8 reports the regression coefficients and p-values for these factors. Figure 3 plots the regression
coefficients with 95% confidence intervals. As expected, higher weight or height was associated with greater cardiac
chamber volumes and aortic areas (p ranges from 10−324 to 4.1×10−15, apart from weight with RAV max). Higher SBP
was associated with greater myocardial mass (LVM: β = 4.8, p = 10−324), greater ventricular volumes (LVEDV: β = 5.8,
p = 2.4×10−130; RVEDV: β = 3.0, p = 4.8×10−32), greater ventricular ejection fractions (LVEF: β = 0.9, p = 4.9×10−49;
RVEF: β = 1.6, p = 1.4×10−161) and lower aortic distensibilities (AAo disten.: β = −0.2, p = 1.1×10−41; DAo disten.:
β =−0.3, p = 2.9×10−53). Smoking, higher alcohol intake and more frequent vigorous PA were associated with greater LVM
(p ranges from 6.4×10−132 to 6.7×10−8). Smoking and vigorous PA both were associated with lower left ventricular ejection
fraction (p ranges from 1.1×10−4 to 0.037). Diabetes was associated with lower myocardial mass, lower cardiac chamber
volumes, lower ejection fractions and aortic areas (p ranges from 3.4×10−34 to 0.025, apart from RAEF).
Associations with clinical outcomes
We also explored the associations of cardiac and aortic imaging phenotypes with 12 categories of common diseases, defined by
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Figure 3. Regression coefficients for cardiac and aortic imaging phenotypes on demographics (blue),
anthropometrics (green) and cardiovascular risk factors (red). n = 19,988 subjects were used. For continuous variables,
the coefficient describes the effect per standard deviation of the variable. For binary variables, the coefficient describes the
effect with a change in the variable from 0 to 1. The gray bars denote the 95% confidence interval.
p-values of each imaging phenotype as a risk factor for a common disease as the outcome in logistic regression. Greater LVM
was associated with higher risk of hypertension (OR = 1.66, p = 3×10−84) and cardiac disease (OR = 1.41, p = 1.8×10−19).
Greater cardiac chamber volumes were associated with higher risk of cardiac disease (p ranges from 1.5×10−63 to 0.008) and
with lower risk of diabetes, asthma, COPD and bronchitis (p ranges from 1.3×10−37 to 0.004, apart from LVEDV with asthma).
Greater cardiac chamber ejection fractions were associated with lower risk of cardiac disease and diabetes (p ranges from
2.3×10−107 to 0.028, apart from RAEF with diabetes). Greater aortic areas were associated with higher risk of hypertension (p
ranges from 4.6×10−55 to 1.3×10−19) and lower risk of diabetes (p ranges from 3.7×10−17 to 1.8×10−10). Greater aortic
distensibilities were associated with lower risk of hypertension and high cholesterol (p ranges from 6.6×10−30 to 0.022).
Phenome-wide association study
We performed a phenome-wide association study (PheWAS) to explore the correlations between imaging phenotypes and
11 categories of non-imaging phenotypes of the participants. The non-imaging phenotypes include primary demographics,
early-life factors, education and employment, diet, alcohol, smoking, physical activity, physical measures, self-reported medical
conditions, mental health and cognitive function. Figure 5a shows the Manhattan plot of the univariate correlation p-values (two-
sided) between imaging phenotypes and non-imaging phenotypes and Figure 5b shows the correlation coefficients. Univariate
correlations were performed between M = 82 imaging phenotypes and N = 555 non-imaging phenotypes for M×N = 45,510
times (Supplementary Tables 25 and 26), with 2,617 correlations reaching the Bonferroni threshold for multiple comparisons
(pBonf = 1.1×10−6 for α = 0.05) and 6,481 correlations reaching the false discovery rate (FDR) threshold (pFDR = 0.007 for
α = 0.05).
Supplementary Table 11 lists the five most significant PheWAS associations for each anatomical structure. Higher SBP,
more frequent PA and lower pulse rate were most consistently associated with larger cardiac chamber volumes. Overall health
rating was associated with lower cardiac chamber volumes. Higher birth weight, whole body fat mass and hip circumference
were associated with larger aortic areas.
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Figure 4. Associations of cardiac and aortic imaging phenotypes with common diseases. n = 25,743 subjects were used.
(a) Odds ratio for an imaging phenotype as a risk factor for a common disease as the outcome. Sex, age, weight and height
were adjusted in a logistic regression analysis. (b) The corresponding p-values (two-sided t-test) for odds ratios shown in (a). *:
reaching the FDR threshold (pFDR = 0.017 for α = 0.05); **: reaching the Bonferroni threshold (pBon f = 3.2×10−4 for
α = 0.05).
phenotypes. Supplementary Table 12 presents five most significant PheWAS associations with mental health phenotypes. Risk
taking and neuroticism score were significantly associated with cardiac and aortic phenotypes. Supplementary Table 13 reports
the most significant associations with cognitive performance, assessed as fluid intelligence score, response time or number of
correct trials completed in cognitive tests.
Further exploring associations with birth weight, mental health and cognitive performance
Following the mass univariate characterisation of associations using PheWAS, we selected several novel and most strongly
associated non-imaging phenotypes and performed multiple linear regressions to further investigate their associations with
cardiac and aortic structure and function. We adjusted for sex, age, sex * age, weight, height, SBP, DBP, current smoking
status, alcohol intake, vigorous PA frequency, high cholesterol, diabetes and added the non-imaging phenotypes of interest as
additional independent variables.
Birth weight: Early-life influences and birth weight are associated with later-life cardiovascular disease risk23. A previous,
smaller population study concluded that these can be attributed to influences on general somatic growth24. We investigated this
further. Extended Data Figure 1 shows the conditional plots of imaging phenotypes against birth weight and Supplementary
Table 14 reports detailed regression coefficients and p-values. Even with control for current weight and height as covariates, birth
weight was still significantly associated with myocardial mass and cardiac chamber volumes (LVM: β = 0.5, p = 1.4×10−5;
LVEDV: β = 1.0, p = 7.5×10−7; RVEDV: β = 1.8, p = 7.4×10−15; LAV max: β =−0.7, p = 4.3×10−4; RAV max: β = 1.7,
p = 2.2×10−14) and in particular with aortic areas. Higher birth weight was associated with greater aortic areas (AAo max area:
β = 20.2, p = 10−40; DAo max area: β = 7.1, p = 3.2×10−26) and lower aortic distensibilities (AAo disten.: β = −0.04,
p = 8.8×10−4; DAo disten.: β =−0.1, p = 5.5×10−4).
Risk taking and neuroticism: Symptoms potentially related to the heart and CVDs have an increased prevalence amongst
people with depression and suggestive associations with other psychological states or traits, such as anxiety, stress or anger25.
Here we extend these observations with evidence for more general associations of affective and psychological traits with
cardiac and aortic structure and function (Supplementary Table 15). Risk taking behaviour was associated with greater LVM
(β = 1.0, p = 4.4×10−6) and lower ejection fractions (LVEF: β =−0.3, p = 0.004; RVEF: β =−0.5, p = 1.6×10−7; LAEF:
β =−0.5, p = 0.001; RAEF: β =−0.8, p = 5.3×10−7). Higher neuroticism score was associated with lower cardiac chamber
volumes (LVEDV: β = −0.6, p = 0.002; RVEDV: β = −1.0, p = 9.8×10−7; LAV max: β = −0.4, p = 0.023; RAV max:
β =−0.7, p = 3.7×10−4).
Fluid intelligence: Subclinical population variation in cardiac haemodynamics has been associated with measures of processing
speed and executive function in an Icelandic population26, although both the association and its potential mechanisms remain
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Figure 5. Phenome-wide association study. n = 26,893 subjects were used. (a) Manhattan plot showing the p-values
(two-sided t-test) for correlations between imaging phenotypes and non-imaging phenotypes. The height of each data point
denotes the negative logarithm of the univariate correlation p-value between one imaging phenotype and one non-imaging
phenotype. The area of the data point denotes the absolute value of the Pearson’s correlation coefficient. The colour of the data
point denotes the anatomical structure of the imaging phenotype. The Bonferroni threshold for multiple comparisons
(α = 0.05) is shown as a dashed horizontal line. (b) Plot showing the Pearson’s correlation coefficients between imaging
phenotypes and non-imaging phenotypes. The height of each data point denotes the correlation coefficient and the area denotes
the negative logarithm of the p-value (two-sided t-test).
controversial27. With the greater statistical power afforded by this large population study, we have found similar and much
stronger associations in a UK population (Supplementary Table 16). Higher fluid intelligence score was strongly associated with
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greater LVM (β = 0.8, p = 1.8×10−18) and greater cardiac chamber volumes (LVEDV: β = 1.1, p = 3.3×10−10; RVEDV:
β = 2.0, p = 2×10−26; RAV max: β = 1.6, p = 1.9×10−20). We further performed a mediation analysis (Extended Data
Figure 2), regressing fluid intelligence score against the LVM, using the brain volume as a mediator and adjusting for the
same covariates. In this model, higher LVM was strongly associated with greater brain volume (β = 0.189, p = 1.3×10−53),
which was associated with higher fluid intelligence score (β = 0.330, p = 3.7×10−49). Approximately one-fourth (26%) of the
association between LVM and fluid intelligence score was mediated by brain volume.
Mendelian randomisation
By leveraging the SNPs associated with risk factors as instrumental variables and the genetic data from UK Biobank, we
performed two-sample Mendelian randomisation analysis to investigate the relationships between risk factors and cardiac
or aortic imaging phenotypes. Five risk factors, which have publicly available genetic association statistics that are needed
for Mendelian randomisation, were investigated (Supplementary Tables 18). Three Mendelian methods were used, including
inverse-variance weighting (IVW), weighted median (WM) and MR-Egger. Comparisons of heterogeneity statistics28 suggested
that IVW and MR-Egger fitted equally well in most of the Mendelian randomisation analyses with the ratio statistic QR being
close to 1. Supplementary Table 17 compares the effect sizes and p-values of Mendelian randomisation (detailed results in
Supplementary Table 19) to observational analysis results. Higher SBP was associated with greater LVM (IVW: β = 4.8,
p = 0.006; WM: β = 4.6, p = 0.044) and lower AAo distensibility (IVW: β =−0.3, p = 0.042; WM: β =−0.4, p = 0.048)
with the same effect direction as conventional observational associations. Diabetes was associated with lower AAo max area
(IVW: β =−12.0, p = 0.003) and with the same effect direction as the observational association. However, findings for SBP
and diabetes were not significant after Bonferroni correction for multiple testing (pBonf = 1.4× 10−3 for α = 0.05). Birth
weight was associated with LVM, LVEDV, RVEDV and AAo max area (IVW and WM: p ranges from p = 6.2×10−8 to 0.049)
and with consistent effect directions to those seen with observational analyses. The findings for birth weight using the IVW
method sustained after adjustment for multiple testing and also with QR > 0.98. The effect directions of risk taking and fluid
intelligence on imaging phenotypes were mostly consistent with observational associations, although the effects were not
statistically significant. The MR-Egger pleiotropy test was only significant for the association between birth weight and AAo
distensibility (p = 0.014).
Discussion
This study makes four major contributions. First, we presented quantitative phenotypes for six anatomical structures of the
heart and aorta on a population-level CMR study, which were extracted using an automated machine learning-based analysis
pipeline. We have returned the derived imaging phenotypes from the 26,893 subjects included in this study to UK Biobank to
be made available for use by other researchers. A data visualisation website was built (https://heartvis.doc.ic.ac.uk), which
allows researchers to explore the associations between imaging phenotypes and non-imaging phenotypes. We have shared the
image analysis pipeline (https://github.com/baiwenjia/ukbb_cardiac), which we anticipate will be a generally valuable resource
for CMR image analysis. Second, we demonstrated the potential informativeness of quantitative cardiac and aortic imaging
phenotypes, which enabled both targeted association studies and a large-scale PheWAS. Third, based on novel observations in
the PheWAS, we reported significant associations of cardiac and aortic phenotypes with a wide range of participant phenotypes,
including birth weight, mental health and cognitive performance measures, illustrating the utility of generating these phenotypes
even from a relatively healthy population when acquired at such a novel scale. Finally, we investigated the effects of these
non-imaging phenotypes on imaging phenotypes using Mendelian randomisation and provided further evidence supporting the
meaningfulness of the observational associations.
Using the imaging phenotypes, we characterised age-related changes in the heart and aorta for women and men. In this
cross-sectional study, ageing was strongly associated with lower volumes of all the four cardiac chambers and with higher
ejection fractions. Compared to cardiac chamber volumes and ejection fractions, aortic distensibilities were even more sensitive
to age. For example, the mean distensibility of the ascending aorta in our population was substantially lower at 70 years
old (1.3×10−3 mmHg−1) than at 50 years old (3.1×10−3 mmHg−1), consistent with the previous finding of an age-related
tendency to increased arterial stiffness29, 30. Women showed a steeper decline of aortic distensibility with age compared to men.
Some study suggested that this may be a consequence of physiological changes after menopause30.
Our study substantially extends findings in22 with association tests over a wider range of structural and functional phenotypes.
We showed strong relationships of cardiac and aortic imaging phenotypes with SBP, smoking, alcohol intake, PA and diabetes,
all of which are well described risk factors for cardiovascular diseases22. Although the percentage of current smokers is
relatively low in this UK Biobank imaging subcohort (3.7%) compared to the full UK Biobank cohort (10.5%)31 or the
general UK population32, we still found a relatively large effect size for smoking, highlighting its association with subclinical
differences in cardiac structure and function33. In addition, due to the large sample size that we have, small signals of influence
on cardiac and aortic anatomy and function are able to be detected. For example, although the effect sizes were relatively small,
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alcohol intake was highly significantly associated with greater myocardial mass, cardiac chamber volumes and aortic areas,
which could not be established in an earlier, smaller population study22.
Additional associations between cardiac or aortic imaging phenotypes and prevalent diseases suggested their potentials
for predicting the risks of diseases. Greater left ventricular mass or cavity volumes were associated with increased risk of
cardiac diseases34. We also found that greater right ventricular volume was associated with increased risks for lung diseases,
including asthma, COPD and bronchitis. This is probably due to the physiological interaction between the heart and the lung,
consistent with previous findings35, 36. Aortic areas and distensibilities, which play important roles in the haemodynamics of
the circulatory system37, were highly associated with the risk of hypertension.
The PheWAS analysis demonstrated that cardiac and aortic imaging phenotypes were significantly correlated with a wide
range of non-imaging phenotypes of the participants. PheWAS is a data-driven way to generate new hypotheses regarding
developmental, life-style, clinical and environmental influences on disease risks through the discovery of their associations
with population variation in cardiac and aortic anatomy and function. Particularly interesting were associations with early-life
development, traits related to mental health and cognitive function. The large population allowed the identification of highly
significant associations of aortic structure with birth weight independent of the general anthropometric measures such as adult
height and weight38. We found associations between higher birth weight and greater aortic area, the diameter of which is a
possible predictor for all cause mortality and incident cardiovascular events39.
The PheWAS also provided novel data for generating hypotheses relating cardiovascular function to mental health. We
found that risk-taking behaviour was significantly associated with greater left ventricular myocardial mass and lower ventricular
and atrial ejection fractions. This could be explained by common co-morbid behaviours such as smoking, drug and alcohol
abuse40, 41, which are independently associated with cardiovascular diseases42, 43. Alternatively, neurogenic factors may
contribute directly to cardiac remodelling44. Associations of risk taking with brain structure and function have been described45.
Our exploration of fluid intelligence score associations supports conclusions of an earlier, smaller study26, suggesting
relationships between cardiovascular and cognitive function. Many studies have already demonstrated the importance of
cardiovascular function in cognition and cognitive diseases6, 46. This may be a consequence of shared risk factors between
dementia and cardiovascular diseases, such as smoking, hypertension, high cholesterol and diabetes47 or direct consequences of
impaired cardiovascular function on the brain48. Our mediation analysis demonstrated a positive association between heart and
brain structure, the latter of which was positively associated with general cognitive ability49.
The Mendelian randomisation analysis provided further evidence for the associations between non-imaging phenotypes
and imaging phenotypes. Perhaps most interesting was the potential causal relationship discovered between birth weight and
cardiac and aortic structures even in mid-later ages. This substantially extends earlier findings that heart size at birth has subtle
but significant and persistent effects on cardiac structure into adulthood50. While the positive association between SBP and left
ventricular mass is consistent with a previous interventional study51, it raises questions about the best interpretation of a more
recent interventional study showing that intensive blood pressure (BP) control and standard BP control reduced left ventricular
mass to a similar extent52. There was a negative association between diabetes and aortic area and distensibility, an observation
that is useful for understanding observations such as the negative relationship of aortic distensibility to all cause mortality53.
However, there are several limitations to our analysis approach and observations. First, the central component of the image
analysis pipeline, the convolutional neural network (CNN), was trained using UK Biobank images20, 21. It is possible to adapt
the pipeline to images scanned on different systems or using different protocols, if training data is available for retraining
or fine-tuning the network54. To apply the pipeline to images with completely unknown characteristics, however, the neural
network is likely to produce less accurate segmentations. In machine learning, this problem is referred to as transfer learning or
domain adaptation and machine learning methods that can reliably address this problem still remain elusive55. Second, the
image analysis pipeline is automated. However, at this point, quality control for the image segmentation, was still performed
manually. A future methodological extension is to develop and incorporate accurate and automated quality control to reduce the
need for this manual intervention. Third, our image analysis pipeline focuses on a limited range of short-axis, long-axis and
aortic cine images, which broadly characterise the cardiac and aortic structure and function. UK Biobank also collects tagged
MR, aortic valve flow and T1 map images, the analysis of which will provide additional imaging phenotypes for the heart and
aorta. Fourth, while Mendelian randomisation analysis may provide support for certain potential causal relationships, more
reliable evidence needs to be provided by interventional research56. In the two-sample Mendelian randomisation analysis, the
genetic associations of SBP, birth weight and risk taking were obtained from meta-analyses on both UK Biobank cohort and
other cohorts (Supplementary Table 18), as findings excluding UK Biobank cohort were not available. This may introduce bias
due to the overlap between the samples for risk factor GWAS and the samples for outcome (imaging phenotype) associations57.
The summed proportion of variance in risk factors explained by all independent SNPs (r2 < 0.1) ranged from 0.25% (risk
taking), 0.46% (SBP) to 3.92% (birth weight) (Supplementary Tables 20-24). The relatively lower proportions of variance
explained for risk taking and SBP may indicate bias due to the overlapping sample. However, since only a UK Biobank
imaging subcohort (n = 22,229) was used for outcome associations, the overlap with the SBP (n = 1,006,863), birth weight
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(n=298,142) or risk taking GWAS cohort (n = 466,571) and the resulting bias may be presumed to be small. For all the other
risk factors used for Mendelian randomisation, the genetic associations were obtained from cohorts other than UK Biobank and
thus without overlapping samples. Finally, the UK Biobank population is a relatively healthy cohort compared to the general
UK population14. The extent to which observations are generalisable to populations with other ethnic mixes or with different
frequencies of co-morbid diseases will need to be explored. The current imaging study focuses on observational associations on
a cross-sectional dataset from a specific population, which may limit its generalisability for estimation of associations in other
populations or making causal inferences. However, a re-imaging project for a subset of 10,000 UK Biobank subjects has just
begun, which will increase its value for longitudinal studies.
In summary, we have developed and applied novel analytical methods to generate quantitative and clinically relevant
phenotypes of the heart and aorta for 26,893 CMR images from the ongoing UK Biobank study. We have defined 2,617
significant associations between imaging phenotypes and non-imaging phenotypes of the participants, which provides a proof
of principle for the use of quantitative imaging phenotypes for more precisely describing relationships between risk factors and
cardiovascular diseases. Our findings provide novel insights into the influence of early-life factors and diabetes on cardiac and
aortic structure and function, as well as the interaction between heart and cognitive phenotypes. We also demonstrate that in
conjunction with data on genetic determinants of individual susceptibilities to life style or co-disease risks, causal relationships
can be better defined using instruments such as Mendelian randomisation and genetic data available from UK Biobank16. A
particular opportunity afforded by UK Biobank is the linkage to the long-term health outcomes of the participants through the
National Health Service (NHS) record. In principle, this should enable extensions of investigations from associations to causal
models for major later-life disorders. The power for such studies will increase rapidly over time. For example, of the 100,000
imaging participants, it was estimated that approximately 5,600 participants will have myocardial infarction (MI) and coronary
death by 2022, rising to 9,400 by 2027 (diabetes: 8,000 rising to 13,600; stroke: 1,800 rising to 4,000; Alzheimer’s disease:
1,800 rising to 6,000)14. The derived imaging phenotypes, together with participant health information and other phenotype and
genotype data, will provide a valuable resource for extension of studies on genetic architecture relevant to the heart, discovering
risk factors and early-stage biomarkers for a variety of diseases and for new understanding in emerging areas of interest, such
as the relationship between late-life heart and brain health.
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UK Biobank is an open access resource, open to bona fide scientists undertaking health-related research that is in the public
good. Ethical approval is obtained from the North West Research Ethics Committee (REC reference: 11/NW/0382) and written
consent is obtained from all participants. The UK Biobank CMR protocol is described in58. In brief, CMR images are acquired
using clinical wide bore 1.5 Tesla scanners (MAGNETOM Aera, Syngo Platform VD13A, Siemens Healthcare, Erlangen,
Germany). The image analysis pipeline consists of several parts, respectively for short-axis, long-axis and aortic cine images,
which provide measures for different anatomical structures.
Short-axis image analysis
The LV, myocardium and RV are segmented on short-axis cine images using a fully convolutional network20, which was trained
on manual annotations of 3,975 subjects. The LV and RV volumes across a cardiac cycle are derived from segmentation, as
illustrated in Figure 1a. The end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV) and ejection fraction
(EF) are determined for both ventricles. The LV myocardial mass is calculated from the myocardial volume using a density of
1.05 g/mL. The myocardial wall thickness is measured on each image slice using the distance between endocardial contour and
epicardial contour at the end-diastolic (ED) frame, illustrated in Figure 1e. The myocardium is divided into 16 AHA segments
according to59. The AHA segment model is a standard model recommended by the American Heart Association (AHA), which
divides the LV into 16 or 17 segments for assessing regional variations of structure and function. Based on the model, the mean
wall thickness for each segment and the global mean wall thickness are calculated.
Motion tracking is performed on short-axis images using non-rigid image registration60 between successive time frames,
using the MIRTK toolkit. The inter-frame displacement fields are composed to obtain the displacement at frame k with regard
to the reference frame, the ED frame or frame 0. To avoid the drift effect due to the accumulation of registration errors61,
motion tracking is performed twice, respectively along the forward direction (tracking starting from frame 0 to frames 1, 2, 3,
· · · ) and backward direction (tracking from frame 0 to frames T −1, T −2, T −3, · · · , where T denotes the number of frames
per cardiac cycle). The average displacement field is calculated by weighted averaging the forward field and backward field,
u0→k(x) = T−kT · u0→k, f orward(x)+
k
T · u0→k,backward(x), where u0→k(x) denotes the displacement from frame 0 to frame k at
pixel x, and T−kT and
k
T denote the weights for the forward and backward displacement fields. For a frame at the early stage of a
cardiac cycle (small k), the forward displacement field will have a higher weight. For a frame at the late stage of a cardiac cycle
(k close to T ), the backward displacement field will have a higher weight.
Three images slices are used for motion tracking, namely a basal slice at 25% of the LV length (the distance from the
mitral annular plane to the apex of the LV), a mid-cavity slice at 50% and an apical slice at 75% of the LV length, according
to62, 63. The myocardial contours on the three slices are divided into AHA 16 segments, illustrated in Figure 1f. Based on the
displacement field from motion tracking, myocardial contours at the ED frame are warped onto each time frame of the cardiac
cycle, illustrated in Figure 1g. Circumferential and radial strains are calculated for each time frame based on the change of
length for each line segment according to64, using the equation Edir =
∆Ldir
Ldir
, where dir denotes the direction, Ldir denotes the
length of a line segment along this direction and ∆Ldir denotes its change. The peak strain for each segment and the global peak
strain are calculated.
Long-axis image analysis
The LA and RA are segmented on long-axis 4-chamber (4Ch) view cine images using neural networks20, illustrated in Figure 1b.
The LA and RA 4Ch areas and longitudinal diameters are determined from the segmentation. The LA is also segmented on
long-axis 2-chamber view (2Ch), illustrated in Figure 1c. The LA 2Ch area and longitudinal diameter are also determined. The
LA volume is calculated using the biplane area-length formula V = 83π ·
A2Ch·A4Ch
L , where A2Ch and A4Ch denotes the atrial area
on the 2Ch and 4Ch view, L denotes the longitudinal diameter averaged across two views65, 66. The RA volume is calculated
using V = 83π ·
A24ch
L . The maximum, minimum volumes and the ejection fraction are determined for both atria.
Motion tracking is performed on long-axis 4Ch view images, using the same approach as short-axis image motion tracking.
The longitudinal strain is calculated from 4Ch view motion tracking results. The myocardial contour is divided into 6 segments,
basal septal (1), basal lateral (2), mid septal (3), mid lateral (4), apical septal (5) and apical lateral (6), illustrated in Figure 1h.
The peak strain for each segment and the global peak strain are calculated.
Aortic image analysis
The AAo and DAo are segmented on aortic cine images using a spatio-termporal neural network21, illustrated in Figure 1d. The
maximum and minimum cross-sectional areas, Amax and Amin, are derived from the segmentation. The aortic distensibility is
calculated by D = Amax−AminAmin·(Pmax−Pmin) , where Pmax denotes the central systolic blood pressure and Pmin denotes the central diastolic
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blood pressure. The central blood pressure is calculated from the brachial blood pressure using Vicorder (Skidmore Medical,
Bristol, UK) by applying a previously described brachial-to-aortic transfer function58.
Quality control
All image segmentations are manually quality controlled by an experienced cardiologist. The segmentation screenshots for
short-axis, long-axis and aortic images at ED and ES frames are visually inspected. Bad segmentations, images with insufficient
coverage of the LV or missing anatomical structures are discarded. For motion tracking, subjects with failed image registration
or outlier peak global strain values (positive circumferential strain, negative radial strain or positive longitudinal strain) are
discarded.
Statistical analysis
Multiple linear regression is used to identify the associations between imaging phenotypes and cardiovascular risk factors, using
the Python statsmodels library. The risk factors are provided by UK Biobank, including sex (31), age (derived using the date
attending assessment centre (53), birth year (34) and birth month (52)), weight (21002), height (50), SBP (4080), DBP (4079),
current smoking status (20116), alcohol intake, vigorous PA frequency (904), high cholesterol and diabetes. The number inside
the parenthesis indicates the UK Biobank field ID. Alcohol intake in the unit of g/day is derived from self-reported alcohol
intake, including average weekly intake of red wine (1568), champagne plus white wine intake (1578), beer plus cider (1588),
spirits (1598) and fortified wine (1608). The quantity of each type of drink is multiplied by its standard drink size and reference
alcohol content, then converted to consumption per day67. High cholesterol is derived from self-reported non-cancer illness
code (20002), using illness code 1473. Diabetes is derived similarly, using illness code 1220, 1221, 1222 and 1223. Mediation
analysis is performed following Baron and Kenny’s steps68 and implemented also using the Python statsmodels library.
In the PheWAS, effects such as age, sex, weight and height are regressed out of the imaging phenotypes, similar to18, as
they may confound with many non-imaging phenotypes. The non-imaging phenotypes are normalised to follow the Gaussian
distribution N(0,1). Univariate cross correlation is then performed between each deconfounded imaging phenotype and each
normalised non-imaging phenotype. The non-imaging phenotypes are grouped into 11 categories similar to18, including primary
demographics (1001), early-life factors (1002), education and employment (1007), diet summary (1004), alcohol summary
(100051), smoking summary (100058), physical activity (100054), physical measure summary (1006), self-reported medical
conditions (1003), mental health (1018), cognitive function (100026). The number inside the parenthesis indicates the UK
Biobank category ID listed at http://biobank.ndph.ox.ac.uk/showcase/cats.cgi. We use all non-imaging phenotypes that are
available to us in our UK Biobank Application 18545 and that belong to the 11 categories. Then we perform data cleaning,
discarding phenotypes with more than 90% missing data and keeping only one phenotype if there are two highly correlated
phenotypes with correlation coefficient > 0.9999.
Mendelian randomisation
Data sources for the genetic associations of each risk factor of interest are presented in Supplementary Table 18, including SBP,
diabetes, birth weight, risk tolerance and fluid intelligence. The genetic instruments, the SNPs, were selected with p < 5×10−8.
For fluid intelligence, due to the lack of genetic instruments, a p-value cut-off of 1×10−5 was used. To avoid weak-instrument
bias, we calculated the F-statistics and only included genetic instruments with an F-statistic > 10. We removed correlated SNPs
(r2 > 0.1) by keeping the SNP with the smallest p-value for the association with the risk factor of interest. Supplementary
Tables 20-24 list the SNPs used for each risk factor. Genetic associations of imaging phenotypes were performed among
genotyped Caucasian, adjusting for sex, age, height and genetic principal components. Three Mendelian randomisation methods
were used56: inverse-variance weighting (IVW), weighted median (WM) and MR-Egger69, 70. We assessed the heterogeneity
statistics Q for IVW, Q′ for MR-Egger and calculated the ratio statistic QR = Q′/Q for model selection28. A QR close to 1
indicates that IVW and MR-Egger models fit the data equally well, whereas a QR much less than 1 indicates that MR-Egger
is better fitting. MR-PRESSO was used to identify outlier SNPs71. Outlier SNPs identified by MR-PRESSO were excluded
from the analysis. Analysis was performed using the TwoSampleMR package in R72. We adjusted for multiple testing of 5 risk
factors and 7 imaging phenotypes using Bonferroni correction.
Data and code availability
The raw imaging data and non-imaging participant characteristics are available from UK Biobank via a standard applica-
tion procedure at http://www.ukbiobank.ac.uk/register-apply. The image analysis code is available at https://github.com/
baiwenjia/ukbb_cardiac. For PheWAS, category IDs and field IDs are defined in ukb_field_categories.py and included in




Further information on research design is available in the Life Sciences Reporting Summary linked to this paper.
Acknowledgements
We would like to thank He Gao, Deborah Schneider-Luftman, Timothy J.W. Dawes and Arinbjorn Kolbeinsson for fruitful
discussion. This research was conducted using the UK Biobank Resource under Application Number 18545, using methods
developed under Application Number 18545 or 2964. Images were reproduced by kind permission of UK Biobank. We
wish to thank all UK Biobank participants and staff. This work is supported by the SmartHeart EPSRC Programme Grant
(EP/P001009/1) and the Imperial BHF Centre of Excellence Grant (RE/18/4/34215). H.S. is supported by a research fellowship
from the Uehara Memorial Foundation. D.P.O. is supported by the Medical Research Council (MC-A651-53301) and British
Heart Foundation (NH/17/1/32725, RG/19/6/34387, RE/18/4/34215). P.M.M. gratefully acknowledges support from the
Edmond J. Safra Foundation and Lily Safra, the Imperial College Healthcare Trust Biomedical Research Centre, the EPSRC
Centre for Mathematics in Precision Healthcare and the UK Dementia Research Institute.
Author contributions
W.B. developed the analysis pipeline and wrote the manuscript; H.S. performed manual quality control of image segmentations
and provided advice on clinical research; J.H. performed Mendelian randomisation; K.F. provided support on genetic data
analysis; S.W. developed the data visualisation website; G.T. and Y.G. provided advice and support on the computational
methodology; F.G. provided support on data management; H.S., N.A., K.F., S.E.P., S.K.P., S.N., K.K., A.D., D.P.O’R. and
M.R.W. provided advice and support on clinical research; W.B., P.M.M. and D.R. conceived and designed the study. All authors
read, contributed to revision and approved the manuscript.
Competing interests statement
S.E.P. acknowledges consultancy fees from Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. P.M.M. acknowledges
consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or speakers’ honoraria
from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and
Nodthera. He is a member of the Scientific Advisory Board to the Board of Ipsen Pharmaceuticals. The remaining authors
declare no competing interests.
References
58. Petersen, S. E. et al. UK Biobank’s cardiovascular magnetic resonance protocol. J. Cardiovasc. Magn. Reson. 18, 8 (2015).
59. Cerqueira, M. D. et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart.
Circulation 105, 539–542 (2002).
60. Rueckert, D. et al. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Transactions
on Med. Imaging 18, 712–21 (1999).
61. Tobon-Gomez, C. et al. Benchmarking framework for myocardial tracking and deformation algorithms: An open access
database. Med. Image Analysis 17, 632–648 (2013).
62. Taylor, R. J. et al. Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance: normal values.
Eur. Hear. J. - Cardiovasc. Imaging 16, 871–881 (2015).
63. Schuster, A. et al. Cardiovascular magnetic resonance feature-tracking assessment of myocardial mechanics: Intervendor
agreement and considerations regarding reproducibility. Clin. Radiol. 70, 989–998 (2015).
64. Puyol-Anton, E. et al. Fully automated myocardial strain estimation from cine MRI using convolutional neural networks.
In IEEE International Symposium on Biomedical Imaging, 1139–1143 (2018).
65. Tsang, T. S. et al. Prediction of cardiovascular outcomes with left atrial size. J. Am. Coll. Cardiol. 47, 1018–1023 (2006).
66. Maceira, A. M., Cosín-Sales, J., Roughton, M., Prasad, S. K. & Pennell, D. J. Reference left atrial dimensions and volumes
by steady state free precession cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 12, 65 (2010).
67. Evangelou, E. et al. New alcohol-related genes suggest shared genetic mechanisms with neuropsychiatric disorders. Nat.
Hum. Behav. 3, 950–961 (2019).
68. Baron, R. M. & Kenny, D. A. The moderator-mediator variable distinction in social psychological research: Conceptual,
strategic, and statistical considerations. J. Pers. Soc. Psychol. 51, 1173–1182 (1986).
69. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some
invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304–314 (2016).
15/30
70. Burgess, S. & Thompson, S. G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur. J.
Epidemiol. 32, 377–389 (2017).
71. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships
inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50, 693–698 (2018).
72. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7 (2018).
73. Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.
Nat. Genet. 50, 1412–1425 (2018).
74. Morris, A. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of
type 2 diabetes. Nat. Genet. 44, 981–990 (2012).
75. Warrington, N. M. et al. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk
factors. Nat. Genet. 51, 804–814 (2019).
76. Linnér, R. K. et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals
identify hundreds of loci and shared genetic influences. Nat. Genet. 51, 245–257 (2019).
77. Davies, G. et al. Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Mol.
Psychiatry 16, 996–1005 (2011).
16/30
Extended Data Figures
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Extended Data Figure 1. The conditional plots of imaging phenotypes against birth weight. n = 12,169 subjects were
used with available birth weight information. The blue line denotes the conditional plot of an imaging phenotype against birth
weight, with other variables (sex, age, sex * age, weight, height, SBP, DBP, current smoking status, alcohol intake, vigorous PA
frequency, high cholesterol and diabetes) set to their mean. The grey area denotes the 95% confidence interval. The p-values
were calculated from two-sided t-tests.
Extended Data Figure 2. Mediation model for LVM, brain volume and fluid intelligence score. n = 18,369 subjects
were used with available fluid intelligence information. The relationship between LVM and fluid intelligence score (path c) is
26% (difference between c and c’) mediated by total brain volume. The values are depicted as regression coefficient (two-sided
t-test p-value) for standardised imaging phenotypes.
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Supplementary Tables
For analysis After quality control
Short-axis image 26,904 26,521 (98.6%)
Long-axis image 26,602 26,240 (98.6%)
Aortic image 26,300 25,673 (97.6%)
Supplementary Table 1. Number of subjects with available raw images for analysis and after quality control. In
total, imaging phenotypes were available for 26,893 subjects after quality control.
Women (n = 13,969) Men (n = 12,924)
Age (year) 62.8 (7.4) 64.2 (7.6)
Race (%)
Caucasian 97.4 96.8
Other ethnicities 2.4 2.9
Unknown 0.2 0.4
Weight (kg) 69.2 (13.1) 83.9 (13.5)
Height (cm) 162.7 (6.2) 176.1 (6.6)
BMI (kg/m2) 26.2 (4.8) 27.0 (3.9)
SBP (mmHg) 133.9 (18.5) 140.6 (16.8)
DBP (mmHg) 77.3 (10.0) 80.9 (9.8)
Life-style
Current smoking (%) 3.1 4.3
Alcohol intake (gram per day) 13.3 (12.3) 26.1 (22.0)
Vigorous PA (days per week) 1.8 (1.8) 2.2 (1.9)
Self-reported diseases
Hypertension (%) 17.9 26.4
High cholesterol (%) 9.0 14.3
Cardiac disease (%) 3.9 8.8
PVD (%) 0.0 0.2
Diabetes (%) 3.1 6.3
Stroke (%) 0.8 1.3
Asthma (%) 10.1 9.3
COPD (%) 0.4 0.8
Bronchitis (%) 1.8 1.8
Parkinson’s (%) 0.1 0.2
Dementia (%) 0.0 0.1
Depression (%) 9.9 5.8
Supplementary Table 2. Basic participant characteristics. n = 26,893 subjects were used. Values are depicted as mean
(standard deviation). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PA: physical
activity; PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease.
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Women (n = 13,969) Men (n = 12,924)
Left ventricle
LV end-diastolic volume (mL) 129.5 (22.5) 168.8 (32.1)
LV end-systolic volume (mL) 50.5 (12.6) 71.5 (19.4)
LV stroke volume (mL) 79.0 (14.4) 97.3 (19.3)
LV ejection fraction (%) 61.1 (5.6) 57.8 (6.1)
LV cardiac output (L/min) 5.0 (1.1) 5.9 (1.3)
LV myocardial mass (g) 70.9 (12.2) 102.9 (18.3)
LV wall thickness (mm) 5.2 (0.5) 6.2 (0.7)
Global peak strain Ecc (%) -23.4 (3.0) -21.1 (3.2)
Global peak strain Err (%) 47.5 (7.8) 42.2 (7.8)
Global peak strain Ell (%) -19.1 (2.7) -17.8 (2.6)
Right ventricle
RV end-diastolic volume (mL) 134.2 (24.3) 181.3 (33.3)
RV end-systolic volume (mL) 54.9 (13.4) 81.4 (19.4)
RV stroke volume (mL) 79.3 (15.1) 99.9 (20.0)
RV ejection fraction (%) 59.3 (5.7) 55.2 (5.9)
Left atrium
LA maximal volume (mL) 67.6 (19.2) 78.7 (25.8)
LA minimal volume (mL) 26.5 (12.0) 32.4 (17.9)
LA stroke volume (mL) 41.1 (10.1) 46.3 (12.7)
LA ejection fraction (%) 61.9 (8.6) 60.5 (9.7)
Right atrium
RA maximal volume (mL) 75.2 (19.5) 97.8 (29.8)
RA minimal volume (mL) 38.1 (12.5) 54.7 (20.8)
RA stroke volume (mL) 37.1 (11.1) 43.1 (14.4)
RA ejection fraction (%) 49.5 (8.8) 44.6 (9.0)
Ascending aorta
AAo maximal area (mm2) 775.9 (156.0) 925.3 (189.5)
AAo minimal area (mm2) 703.3 (155.1) 841.8 (185.9)
AAo distensibility (10−3 mmHg−1) 1.9 (1.5) 1.9 (1.2)
Descending aorta
DAo maximal area (mm2) 421.4 (71.0) 529.5 (91.6)
DAo minimal area (mm2) 368.3 (68.3) 468.2 (87.3)
DAo distensibility (10−3 mmHg−1) 2.5 (1.7) 2.5 (1.4)
Supplementary Table 3. Statistics of global imaging phenotypes for the heart and aorta. n = 26,893 subjects were
used. The values are depicted as mean (standard deviation).
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Segment
Women (n = 13,969) Men (n = 12,924)
Wall thickness (mm) Wall thickness (mm)
Basal
1 6.1 (0.9) 7.2 (1.1)
2 4.6 (1.0) 5.3 (1.2)
3 4.9 (1.0) 5.7 (1.1)
4 5.6 (0.8) 6.8 (1.0)
5 5.8 (0.7) 6.8 (0.8)
6 5.8 (0.7) 6.8 (0.9)
Mid
7 5.1 (0.6) 6.2 (0.8)
8 5.7 (0.7) 6.9 (0.9)
9 5.9 (0.8) 7.2 (1.0)
10 5.4 (0.7) 6.6 (0.8)
11 5.2 (0.6) 6.2 (0.8)
12 5.1 (0.6) 6.1 (0.8)
Apical
13 4.2 (0.6) 5.1 (0.7)
14 4.4 (0.6) 5.3 (0.7)
15 4.1 (0.6) 5.0 (0.7)
16 4.3 (0.6) 5.2 (0.7)
Global 5.2 (0.5) 6.2 (0.7)
Supplementary Table 4. Statistics of regional and global myocardial wall thickness. n = 26,893 subjects were used.
The values are depicted as mean (standard deviation).
Segment
Women (n = 13,969) Men (n = 12,924)
Ecc (%) Err (%) Ecc (%) Err (%)
Basal
1 -23.9 (5.2) 39.3 (12.9) -22.3 (5.3) 35.5 (12.8)
2 -23.9 (6.6) 30.6 (11.6) -18.2 (6.9) 24.6 (11.2)
3 -20.3 (6.1) 35.6 (13.2) -19.0 (5.2) 27.4 (13.0)
4 -19.0 (5.9) 62.7 (17.8) -19.1 (5.4) 51.4 (16.0)
5 -27.6 (5.2) 67.6 (16.2) -25.0 (5.3) 60.1 (14.3)
6 -27.1 (5.5) 56.3 (18.7) -26.0 (5.1) 53.9 (16.7)
Mid
7 -27.9 (5.3) 52.8 (13.2) -24.7 (5.2) 47.2 (12.6)
8 -27.3 (5.5) 43.7 (10.6) -24.8 (5.4) 40.5 (10.3)
9 -23.5 (7.2) 49.3 (12.1) -21.8 (5.8) 44.3 (11.1)
10 -15.6 (5.0) 51.0 (14.0) -15.5 (4.6) 45.4 (12.4)
11 -22.9 (5.4) 57.1 (12.7) -20.7 (5.3) 50.5 (11.4)
12 -20.3 (5.2) 53.6 (12.9) -18.0 (4.8) 46.7 (12.1)
Apical
13 -30.1 (5.7) 49.9 (13.5) -27.0 (5.9) 47.2 (13.6)
14 -30.9 (5.8) 44.3 (12.6) -28.5 (5.8) 41.8 (13.0)
15 -23.4 (6.5) 58.0 (14.5) -23.8 (6.5) 53.5 (14.0)
16 -26.1 (5.7) 58.0 (13.5) -24.9 (6.0) 54.7 (13.4)
Global -23.4 (3.0) 47.5 (7.8) -21.1 (3.2) 42.2 (7.8)
Supplementary Table 5. Statistics of regional and global peak circumferential strain Ecc and peak radial strain Err.
n = 26,893 subjects were used. The values are depicted as mean (standard deviation).
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Segment
Women (n = 13,969) Men (n = 12,924)
Ell (%) Ell (%)
Basal
1 -27.3 (7.2) -27.1 (6.7)
2 -32.6 (7.8) -32.2 (7.0)
Mid
3 -14.3 (5.0) -12.5 (4.9)
4 -18.4 (5.6) -15.1 (5.2)
Apical
5 -11.1 (4.6) -10.6 (4.5)
6 -17.2 (4.7) -15.5 (4.9)
Global -19.1 (2.7) -17.8 (2.6)
Supplementary Table 6. Statistics of regional and global peak longitudinal strain Ell. n = 26,893 subjects were used.
The values are depicted as mean (standard deviation).
LVM (g) LVEDV (mL) LVEF (%) RVEDV (mL) RVEF (%)
Sex 53.0[49.8,56.3] (p=3×10−218) 53.1[47.4,58.8] (p=2.9×10−74) -3.2[−3.4,−3.1] (p=10−324) 71.1[65.0,77.2] (p=7.7×10−116) -4.1[−4.2,−3.9] (p=10−324)
Age, per 7.5 yr -1.0[−1.2,−0.7] (p=2.2×10−12) -5.9[−6.4,−5.5] (p=2.5×10−136) 0.3[0.3,0.4] (p=1.1×10−19) -6.1[−6.6,−5.7] (p=4.7×10−130) 0.5[0.4,0.6] (p=1.6×10−37)
Sex * Age, per 7.5 yr -2.4[−2.8,−2.1] (p=5.6×10−36) -1.5[−2.2,−0.8] (p=8.6×10−6) -2.6[−3.3,−1.9] (p=4.6×10−13)
LAV max (mL) LAEF (%) RAV max (mL) RAEF (%)
Sex 10.6[10.1,11.2] (p=2.6×10−297) -0.9[−1.1,−0.7] (p=1.7×10−15) 22.7[22.1,23.3] (p=10−324) -8.9[−10.8,−7.0] (p=1.4×10−19)
Age, per 7.5 yr -2.0[−2.3,−1.7] (p=9.1×10−44) -0.8[−0.9,−0.7] (p=2.3×10−43) -1.0[−1.3,−0.7] (p=1.7×10−9) -0.2[−0.4,−0.1] (p=0.003)
Sex * Age, per 7.5 yr 0.5[0.3,0.7] (p=2.3×10−5)
AAo max area (mm2) AAo distensibility DAo max area (mm2) DAo distensibility
Sex 143.9[139.5,148.3] (p=10−324) -0.9[−1.2,−0.6] (p=2.1×10−10) 104.9[102.8,106.9] (p=10−324) -1.1[−1.5,−0.8] (p=1.7×10−10)
Age, per 7.5 yr 29.3[27.1,31.5] (p=6.1×10−146) -0.7[−0.7,−0.7] (p=10−324) 20.8[19.8,21.9] (p=10−324) -0.8[−0.8,−0.7] (p=10−324)
Sex * Age, per 7.5 yr 0.1[0.1,0.2] (p=8.4×10−14) 0.1[0.1,0.2] (p=10−11)
Supplementary Table 7. Associations of selected imaging phenotypes with sex and age. After excluding
non-Caucasian subjects and subjects with CVDs, n = 23,415 subjects were used with available sex and age information. The
values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test p-value). For continuous variables,
the coefficient describes the effect per standard deviation of the variable. For binary variables, the coefficient describes the
effect with a change in the variable from 0 to 1. Female is coded as 0.
21/30
LVM (g) LVEDV (mL) LVEF (%) RVEDV (mL) RVEF (%)
Sex 30.2[27.4,33.0] (p=10−96) 22.5[17.0,28.0] (p=10−15) -2.5[−2.8,−2.3] (p=3.6×10−89) 41.5[35.6,47.4] (p=3.2×10−43) -3.7[−3.9,−3.5] (p=3.7×10−193)
Age, per 7.5 yr -1.2[−1.4,−0.9] (p=8×10−20) -5.2[−5.6,−4.7] (p=2.3×10−94) -0.0[−0.1,0.1] (p=0.903) -4.2[−4.7,−3.7] (p=3.6×10−56) -0.1[−0.1,0.0] (p=0.250)
Sex * Age, per 7.5 yr -1.6[−1.9,−1.3] (p=4×10−22) -0.9[−1.5,−0.3] (p=0.006) -2.2[−2.9,−1.5] (p=2.7×10−10)
Weight, per 15.1 kg 8.2[8.0,8.4] (p=10−324) 8.4[8.0,8.8] (p=10−324) 0.1[0.0,0.2] (p=0.035) 9.2[8.8,9.7] (p=10−324) -0.4[−0.5,−0.3] (p=1.6×10−12)
Height, per 9.2 cm 3.8[3.5,4.0] (p=3.5×10−172) 10.7[10.2,11.2] (p=10−324) -0.5[−0.7,−0.4] (p=2×10−16) 11.2[10.6,11.7] (p=10−324) -0.1[−0.3,−0.0] (p=0.029)
SBP, per 18.0 mmHg 4.8[4.6,5.1] (p=10−324) 5.8[5.3,6.3] (p=2.4×10−130) 0.9[0.8,1.0] (p=4.9×10−49) 3.0[2.5,3.5] (p=4.8×10−32) 1.6[1.5,1.7] (p=1.4×10−161)
DBP, per 10.0 mmHg -1.4[−1.7,−1.2] (p=5.5×10−35) -5.4[−5.8,−4.9] (p=1.1×10−120) -0.7[−0.8,−0.6] (p=5.8×10−38) -4.3[−4.8,−3.8] (p=4.3×10−68) -0.8[−0.9,−0.7] (p=1.3×10−45)
Smoking status 2.4[1.5,3.2] (p=6.7×10−8) -1.3[−3.0,0.3] (p=0.118) -0.4[−0.9,−0.0] (p=0.037) -4.4[−6.2,−2.6] (p=1.2×10−6) -0.4[−0.8,0.1] (p=0.086)
Alcohol, per 18.7 g/d 1.0[0.8,1.1] (p=3.4×10−27) 1.4[1.1,1.8] (p=7.7×10−17) -0.0[−0.1,0.0] (p=0.364) 1.1[0.7,1.5] (p=3.9×10−9) 0.0[−0.1,0.1] (p=0.472)
PA, per 1.9 d/w 2.1[1.9,2.3] (p=6.4×10−132) 4.3[3.9,4.6] (p=7.1×10−144) -0.2[−0.2,−0.1] (p=1.1×10−4) 4.7[4.3,5.0] (p=2.1×10−150) -0.2[−0.3,−0.1] (p=3.2×10−8)
High cholesterol -0.4[−0.9,0.1] (p=0.138) -2.8[−3.9,−1.8] (p=7.4×10−8) 0.2[−0.1,0.4] (p=0.230) -2.9[−4.0,−1.8] (p=3.5×10−7) 0.3[0.0,0.5] (p=0.046)
Diabetes -1.0[−1.8,−0.1] (p=0.025) -8.7[−10.3,−7.0] (p=1.4×10−24) -1.0[−1.4,−0.5] (p=5.1×10−6) -11.1[−12.9,−9.3] (p=3.4×10−34) -0.7[−1.1,−0.3] (p=5×10−4)
LAV max (mL) LAEF (%) RAV max (mL) RAEF (%)
Sex -1.0[−1.8,−0.1] (p=0.033) 0.7[0.4,1.1] (p=1.1×10−4) 9.0[8.0,10.0] (p=8.2×10−67) -8.7[−10.7,−6.6] (p=5.4×10−16)
Age, per 7.5 yr -2.3[−2.6,−1.9] (p=7.2×10−43) -1.0[−1.1,−0.8] (p=1.4×10−43) 0.8[0.4,1.1] (p=5.6×10−5) -0.7[−0.9,−0.5] (p=2.1×10−13)
Sex * Age, per 7.5 yr 0.6[0.3,0.8] (p=2×10−6)
Weight, per 15.1 kg 7.8[7.4,8.2] (p=10−324) -0.9[−1.1,−0.8] (p=3.2×10−31) -0.4[−0.8,0.0] (p=0.078) 0.1[−0.1,0.2] (p=0.344)
Height, per 9.2 cm 1.8[1.4,2.3] (p=4.1×10−15) -0.4[−0.6,−0.2] (p=1.8×10−5) 9.7[9.1,10.2] (p=2.8×10−280) -0.9[−1.1,−0.7] (p=1.5×10−18)
SBP, per 18.0 mmHg 4.8[4.4,5.3] (p=8.3×10−115) -0.0[−0.2,0.1] (p=0.647) -0.1[−0.6,0.4] (p=0.713) 0.9[0.7,1.0] (p=3.9×10−21)
DBP, per 10.0 mmHg -4.1[−4.5,−3.7] (p=1.7×10−88) 0.5[0.3,0.6] (p=8.9×10−8) -1.5[−2.0,−1.1] (p=6.6×10−11) 0.0[−0.1,0.2] (p=0.738)
Smoking status -3.5[−5.0,−2.1] (p=2.9×10−6) -0.2[−0.9,0.4] (p=0.436) -5.4[−7.1,−3.7] (p=5.3×10−10) 0.1[−0.6,0.7] (p=0.835)
Alcohol, per 18.7 g/d 1.1[0.8,1.4] (p=4.5×10−13) -0.2[−0.3,−0.1] (p=0.003) 0.6[0.2,0.9] (p=7.6×10−4) -0.1[−0.3,−0.0] (p=0.035)
PA, per 1.9 d/w 2.6[2.3,2.9] (p=9.7×10−69) -0.4[−0.5,−0.2] (p=3.4×10−9) 3.1[2.8,3.4] (p=3.9×10−74) -0.5[−0.7,−0.4] (p=1.8×10−17)
High cholesterol -1.7[−2.6,−0.8] (p=3.7×10−4) 0.3[−0.1,0.7] (p=0.111) -3.3[−4.3,−2.2] (p=1.6×10−9) 0.3[−0.1,0.7] (p=0.196)
Diabetes -3.5[−5.0,−2.1] (p=2.6×10−6) -1.1[−1.7,−0.4] (p=9.3×10−4) -7.2[−8.9,−5.5] (p=1.1×10−16) -0.0[−0.6,0.6] (p=0.960)
AAo max area (mm2) AAo distensibility DAo max area (mm2) DAo distensibility
Sex 42.2[35.2,49.2] (p=8.7×10−32) -0.6[−0.9,−0.2] (p=5.5×10−4) 49.1[45.9,52.2] (p=2.5×10−197) -0.7[−1.0,−0.3] (p=7×10−4)
Age, per 7.5 yr 44.0[41.4,46.6] (p=3.7×10−241) -0.7[−0.7,−0.6] (p=10−324) 27.2[26.0,28.3] (p=10−324) -0.7[−0.7,−0.6] (p=10−324)
Sex * Age, per 7.5 yr 0.1[0.1,0.1] (p=3.9×10−8) 0.1[0.1,0.1] (p=6.7×10−6)
Weight, per 15.1 kg 36.6[33.6,39.6] (p=1.8×10−122) 0.0[0.0,0.1] (p=2.4×10−4) 26.2[24.9,27.6] (p=1.6×10−300) -0.0[−0.1,−0.0] (p=0.023)
Height, per 9.2 cm 29.5[25.9,33.1] (p=2.2×10−57) -0.1[−0.1,−0.0] (p=1.5×10−5) 14.3[12.7,16.0] (p=3.2×10−66) 0.0[−0.0,0.1] (p=0.335)
SBP, per 18.0 mmHg -13.5[−16.8,−10.2] (p=1.2×10−15) -0.2[−0.2,−0.2] (p=1.1×10−41) -0.2[−1.7,1.3] (p=0.783) -0.3[−0.3,−0.2] (p=2.9×10−53)
DBP, per 10.0 mmHg 40.5[37.3,43.6] (p=2.4×10−135) -0.1[−0.1,−0.1] (p=2.2×10−15) 10.8[9.4,12.3] (p=2.5×10−49) -0.1[−0.1,−0.0] (p=1.9×10−6)
Smoking status 10.3[−1.6,22.2] (p=0.090) 0.0[−0.1,0.1] (p=0.636) 14.5[9.1,19.9] (p=1.3×10−7) 0.1[−0.0,0.2] (p=0.054)
Alcohol, per 18.7 g/d 11.7[9.3,14.1] (p=1.6×10−21) -0.0[−0.0,0.0] (p=0.076) 4.4[3.3,5.4] (p=3.3×10−15) -0.0[−0.1,−0.0] (p=0.010)
PA, per 1.9 d/w 10.5[8.2,12.8] (p=5.2×10−19) 0.0[0.0,0.1] (p=1.5×10−5) 6.3[5.3,7.4] (p=4.9×10−33) 0.0[0.0,0.1] (p=5.9×10−5)
High cholesterol -0.0[−7.3,7.3] (p=0.998) -0.0[−0.1,0.1] (p=0.955) -5.1[−8.3,−1.8] (p=0.003) -0.0[−0.1,0.1] (p=0.799)
Diabetes -19.7[−31.5,−7.9] (p=0.001) 0.0[−0.1,0.1] (p=0.991) -17.6[−22.9,−12.3] (p=8.9×10−11) -0.1[−0.2,0.1] (p=0.317)
Supplementary Table 8. Associations of imaging phenotypes with cardiovascular risk factors. n = 19,988 subjects
were used with available information for all independent variables. The values are depicted as regression coefficient β [95%
confidence interval] (two-sided t-test p-value). Independent variables include sex, age, weight, height, systolic blood pressure
(SBP), diastolic blood pressure (DBP), current smoking status, alcohol intake, vigorous physical activity (PA) frequency, high
cholesterol, diabetes. For continuous variables, the coefficient describes the effect per standard deviation of the variable. For
binary variables, the coefficient describes the effect with a change in the variable from 0 to 1. Female is coded as 0.
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LVM LVEDV LVEF RVEDV RVEF
per 22.2 g per 33.8 mL per 6.1 % per 37.3 mL per 6.1 %
Hypertension 1.66[1.58,1.75] (p=3×10−84) 1.05[1.01,1.09] (p=0.024) 1.10[1.07,1.13] (p=2×10−10) 0.96[0.92,1.00] (p=0.072) 1.14[1.11,1.18] (p=6.2×10−17)
High cholesterol 0.97[0.91,1.03] (p=0.361) 0.87[0.82,0.92] (p=2.1×10−7) 1.00[0.96,1.03] (p=0.869) 0.86[0.82,0.91] (p=4×10−7) 1.01[0.97,1.05] (p=0.534)
Cardiac disease 1.41[1.31,1.53] (p=1.8×10−19) 1.44[1.36,1.53] (p=8.3×10−33) 0.76[0.72,0.79] (p=4.2×10−35) 1.10[1.03,1.18] (p=0.008) 0.84[0.80,0.88] (p=8.1×10−14)
PVD 1.34[0.81,2.21] (p=0.253) 1.44[1.01,2.04] (p=0.044) 0.80[0.59,1.09] (p=0.152) 1.07[0.65,1.76] (p=0.782) 0.81[0.58,1.11] (p=0.186)
Diabetes 0.94[0.86,1.03] (p=0.210) 0.66[0.61,0.72] (p=1.8×10−22) 0.90[0.86,0.95] (p=1.8×10−4) 0.56[0.52,0.62] (p=1.3×10−37) 0.94[0.89,0.99] (p=0.028)
Stroke 0.97[0.79,1.17] (p=0.724) 0.91[0.78,1.07] (p=0.259) 0.94[0.84,1.04] (p=0.228) 0.82[0.69,0.97] (p=0.024) 0.90[0.80,1.00] (p=0.056)
Asthma 1.03[0.96,1.10] (p=0.482) 0.95[0.90,1.01] (p=0.074) 0.99[0.95,1.03] (p=0.527) 0.90[0.85,0.96] (p=8.7×10−4) 1.04[1.00,1.09] (p=0.044)
COPD 0.99[0.78,1.27] (p=0.963) 0.69[0.55,0.86] (p=8.8×10−4) 0.88[0.77,1.01] (p=0.069) 0.54[0.42,0.68] (p=2.2×10−7) 0.85[0.74,0.98] (p=0.021)
Bronchitis 0.95[0.81,1.12] (p=0.565) 0.83[0.72,0.94] (p=0.005) 0.90[0.83,0.98] (p=0.019) 0.78[0.68,0.89] (p=3.9×10−4) 0.92[0.85,1.01] (p=0.075)
Parkinson’s 0.64[0.37,1.12] (p=0.117) 1.02[0.69,1.51] (p=0.916) 1.20[0.89,1.62] (p=0.235) 1.13[0.73,1.73] (p=0.583) 1.14[0.83,1.55] (p=0.413)
Dementia 0.25[0.08,0.82] (p=0.023) 0.41[0.17,0.99] (p=0.048) 0.97[0.58,1.62] (p=0.899) 0.47[0.19,1.13] (p=0.090) 1.09[0.63,1.91] (p=0.751)
Depression 0.97[0.90,1.06] (p=0.517) 0.93[0.87,1.00] (p=0.046) 0.98[0.93,1.02] (p=0.279) 0.89[0.83,0.96] (p=0.001) 1.01[0.96,1.06] (p=0.693)
LAV max LAEF RAV max RAEF
per 23.2 mL per 9.1 % per 27.4 mL per 9.2 %
Hypertension 1.10[1.07,1.14] (p=6.5×10−10) 0.99[0.96,1.02] (p=0.362) 0.92[0.89,0.95] (p=9.3×10−7) 1.12[1.08,1.15] (p=8.8×10−13)
High cholesterol 0.92[0.88,0.96] (p=3.8×10−5) 1.01[0.97,1.04] (p=0.758) 0.88[0.84,0.92] (p=2.1×10−8) 1.00[0.96,1.04] (p=0.914)
Cardiac disease 1.49[1.42,1.56] (p=1.5×10−63) 0.61[0.58,0.63] (p=2.3×10−107) 1.28[1.22,1.34] (p=2.2×10−22) 0.71[0.67,0.74] (p=1.8×10−38)
PVD 1.20[0.89,1.61] (p=0.230) 0.70[0.52,0.94] (p=0.017) 1.32[1.01,1.72] (p=0.041) 0.82[0.56,1.19] (p=0.300)
Diabetes 0.87[0.82,0.92] (p=6.3×10−6) 0.92[0.87,0.97] (p=0.002) 0.68[0.64,0.73] (p=1.8×10−25) 1.01[0.95,1.07] (p=0.808)
Stroke 1.01[0.90,1.14] (p=0.873) 0.86[0.78,0.96] (p=0.005) 0.93[0.82,1.07] (p=0.313) 0.84[0.75,0.95] (p=0.005)
Asthma 0.92[0.88,0.96] (p=3.7×10−4) 1.06[1.02,1.11] (p=0.003) 0.93[0.89,0.98] (p=0.004) 1.07[1.02,1.11] (p=0.003)
COPD 0.77[0.64,0.92] (p=0.004) 0.87[0.76,1.00] (p=0.056) 0.73[0.60,0.89] (p=0.001) 1.07[0.92,1.25] (p=0.382)
Bronchitis 0.90[0.81,1.00] (p=0.050) 0.87[0.80,0.94] (p=7.9×10−4) 0.77[0.69,0.86] (p=7.6×10−6) 1.00[0.91,1.10] (p=0.969)
Parkinson’s 1.17[0.90,1.50] (p=0.234) 1.10[0.83,1.45] (p=0.507) 1.16[0.88,1.54] (p=0.284) 1.51[1.16,1.95] (p=0.002)
Dementia 0.77[0.40,1.47] (p=0.422) 0.80[0.50,1.27] (p=0.341) 0.65[0.32,1.32] (p=0.231) 1.03[0.59,1.78] (p=0.920)
Depression 0.94[0.89,0.99] (p=0.019) 0.99[0.95,1.04] (p=0.795) 0.92[0.87,0.97] (p=0.002) 0.99[0.95,1.04] (p=0.801)
AAo max area AAo distensibility DAo max area DAo distensibility
per 188.4 mm2 per 1.4 × 10−3 mmHg−1 per 97.8 mm2 per 1.6 × 10−3 mmHg−1
Hypertension 1.32[1.27,1.36] (p=4.6×10−55) 0.74[0.70,0.78] (p=6.6×10−30) 1.20[1.15,1.25] (p=1.3×10−19) 0.80[0.76,0.84] (p=6.6×10−20)
High cholesterol 0.98[0.94,1.02] (p=0.375) 0.92[0.87,0.98] (p=0.006) 0.90[0.85,0.94] (p=2.9×10−5) 0.94[0.89,0.99] (p=0.022)
Cardiac disease 1.07[1.02,1.14] (p=0.012) 1.05[0.98,1.11] (p=0.164) 0.93[0.88,1.00] (p=0.036) 1.03[0.97,1.10] (p=0.332)
PVD 0.63[0.39,1.03] (p=0.065) 1.03[0.64,1.66] (p=0.913) 0.95[0.59,1.52] (p=0.836) 1.24[0.95,1.63] (p=0.115)
Diabetes 0.79[0.74,0.85] (p=1.8×10−10) 0.93[0.86,1.01] (p=0.080) 0.71[0.66,0.77] (p=3.7×10−17) 0.88[0.81,0.96] (p=0.005)
Stroke 0.98[0.85,1.12] (p=0.764) 0.98[0.83,1.15] (p=0.762) 0.93[0.80,1.08] (p=0.334) 0.89[0.74,1.07] (p=0.201)
Asthma 0.95[0.90,1.00] (p=0.038) 1.01[0.96,1.06] (p=0.724) 0.89[0.84,0.95] (p=1.2×10−4) 0.99[0.94,1.04] (p=0.600)
COPD 0.92[0.76,1.10] (p=0.357) 1.04[0.85,1.27] (p=0.680) 0.87[0.71,1.07] (p=0.182) 1.10[0.93,1.31] (p=0.260)
Bronchitis 0.88[0.79,0.98] (p=0.025) 0.96[0.85,1.08] (p=0.505) 0.94[0.83,1.06] (p=0.304) 0.99[0.88,1.10] (p=0.794)
Parkinson’s 1.00[0.71,1.42] (p=0.997) 0.88[0.53,1.46] (p=0.610) 0.94[0.64,1.39] (p=0.770) 1.04[0.71,1.52] (p=0.844)
Dementia 1.02[0.55,1.91] (p=0.944) 0.58[0.18,1.91] (p=0.372) 1.09[0.55,2.16] (p=0.803) 0.58[0.18,1.87] (p=0.362)
Depression 0.97[0.92,1.02] (p=0.221) 1.02[0.97,1.07] (p=0.519) 0.96[0.90,1.02] (p=0.195) 1.01[0.96,1.06] (p=0.614)
Supplementary Table 9. Associations of cardiac and aortic imaging phenotypes with common diseases. n = 25,743
subjects were used with available disease information. The odds ratio of each imaging phenotype as a risk factor for a common
disease as outcome is reported. Sex, age, weight and height were adjusted in logistic regression. The values are depicted as











1075 Heart attack/myocardial infarction




1484 Wolff Parkinson white/WPW syndrome
1485 Irregular heart beat
1486 Sick sinus syndrome
1487 SVT/supraventricular tachycardia
1078 Heart valve problem/heart murmur
1584 Mitral valve disease
1585 Mitral regurgitation/incompetence
1586 Aortic valve disease
1587 Aortic regurgitation/incompetence
1079 Cardiomyopathy





1067 Peripheral vascular disease
1087 Leg claudication/intermittent claudication
1088 Arterial embolism
1492 Aortic aneurysm





1222 Type 1 diabetes












1496 Alpha-1 antitrypsin deficiency
Parkinson’s 1262 Parkinson’s disease




Supplementary Table 10. Categories of common diseases in participants. Defined by self-reported disease code (UK
Biobank field ID 20002). 24/30
Structure − log10(p) r Imaging phenotype Non-imaging phenotype Field ID
LV
319.4 0.26 LVM Systolic blood pressure 4080-2.0
307.7 -0.33 LVEDV Pulse rate 4194-2.0
226.5 0.22 Wall thickness AHA 9 Diastolic blood pressure 4079-2.0
160.8 0.17 LVEDV Number of days/week of vigorous physical activity 904-2.0
69.8 0.11 LVEDV Number of days/week of moderate physical activity 884-2.0
RV
307.7 -0.33 RVEDV Pulse rate 4194-2.0
180.0 0.18 RVEDV Number of days/week of vigorous physical activity 904-2.0
133.3 0.17 RVEF Systolic blood pressure 4080-2.0
73.6 -0.11 RVEDV Overall health rating 2178-2.0
70.0 0.11 RVEDV Number of days/week of moderate physical activity 884-2.0
LA
307.7 -0.25 LAV max Pulse rate 4194-2.0
83.8 0.12 LASV Number of days/week of vigorous physical activity 904-2.0
68.1 0.11 LASV Systolic blood pressure 4080-0.0
33.9 0.08 LASV Number of days/week of moderate physical activity 884-2.0
29.4 -0.07 LASV Overall health rating 2178-2.0
RA
213.4 -0.20 RAV min Pulse rate 4194-2.0
82.0 0.12 RAV min Number of days/week of vigorous physical activity 904-2.0
45.4 0.10 RAEF Systolic blood pressure 4080-2.0
41.7 -0.12 RAV min Types of physical activity in last 4 weeks 6164-0.2
36.7 -0.08 RAV max Overall health rating 2178-0.0
AAo
260.1 0.22 AAo min area Diastolic blood pressure 4079-0.0
128.5 -0.18 AAo distensibility Systolic blood pressure 4080-2.0
46.2 -0.11 AAo distensibility Pulse rate 102-2.0
45.1 0.12 AAo min area Birth weight 20022-0.0
37.5 0.08 AAo max area Whole body fat mass 23100-0.0
DAo
167.6 0.19 DAo min area Diastolic blood pressure 4079-2.0
130.0 -0.18 DAo distensibility Systolic blood pressure 4080-2.0
82.0 -0.13 DAo max area Pulse rate 102-0.1
64.3 0.11 DAo max area Whole body fat mass 23100-0.0
60.5 0.10 DAo max area Hip circumference 49-0.0
Supplementary Table 11. Five most significant PheWAS associations for each anatomical structure. n = 26,893
subjects were used. Note that if a non-imaging phenotype has multiple associations with imaging phenotypes of the same
anatomical structure, only the top association is shown. For example, systolic blood pressure is significantly associated with
several LV imaging phenotypes, including LVM, LVEDV, LVSV etc, but only the top association (lowest p-value) is shown,
which is (LVM, Systolic blood pressure). Columns 2 and 3 denote the negative logarithm of correlation p-value (two-sided
t-test) and Pearson’s correlation coefficient r. Field ID denotes the UK Biobank code for the non-imaging phenotype.
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Structure − log10(p) r Imaging phenotype Non-imaging phenotype Field ID
LV
13.4 0.05 Wall thickness Global Risk taking 2040-2.0
11.1 -0.04 LVEDV Happiness 4526-2.0
8.7 -0.04 LVEDV Neuroticism score 20127-0.0
8.3 -0.04 LVSV Seen doctor (GP) for nerves, anxiety, tension or depression 2090-2.0
7.5 -0.03 LVEDV Ever depressed for a whole week 4598-2.0
RV
16.5 -0.06 RVEDV Neuroticism score 20127-0.0
13.6 0.05 RVESV Risk taking 2040-2.0
12.1 -0.05 RVEDV Frequency of depressed mood in last 2 weeks 2050-0.0
10.7 -0.04 RVEDV Happiness 4526-2.0
9.0 -0.04 RVEDV Seen doctor (GP) for nerves, anxiety, tension or depression 2090-0.0
LA
10.5 -0.04 LAV max Happiness 4526-2.0
10.2 -0.04 LASV Frequency of depressed mood in last 2 weeks 2050-2.0
6.8 -0.04 LASV Neuroticism score 20127-0.0
6.4 -0.03 LASV Seen a psychiatrist for nerves, anxiety, tension or depression 2100-2.0
6.4 -0.03 LAEF Risk taking 2040-2.0
RA
14.5 -0.05 RAEF Risk taking 2040-2.0
10.9 -0.05 RAV max Neuroticism score 20127-0.0
8.3 -0.04 RAV max Frequency of depressed mood in last 2 weeks 2050-0.0
6.7 -0.03 RAV max Seen doctor (GP) for nerves, anxiety, tension or depression 2090-2.0
5.1 -0.03 RASV Seen a psychiatrist for nerves, anxiety, tension or depression 2100-0.0
AAo
4.6 0.03 AAo max area Risk taking 2040-0.0
2.9 0.04 AAo max area Substances taken for depression 20546-0.1
1.9 0.05 AAo max area Substances taken for anxiety 20549-0.1
1.6 0.03 AAo distensibility Frequency of depressed mood in last 2 weeks 2050-1.0
1.4 0.03 AAo distensibility Ever depressed for a whole week 4598-1.0
DAo
5.4 -0.03 DAo max area Happiness 4526-2.0
5.3 0.03 DAo max area Risk taking 2040-0.0
1.9 -0.02 DAo min area Ever depressed for a whole week 4598-2.0
1.9 0.03 DAo max area Substances taken for depression 20546-0.1
1.9 -0.02 DAo max area Frequency of depressed mood in last 2 weeks 2050-0.0
Supplementary Table 12. Five most significant PheWAS associations in the mental health category for each
anatomical structure. n = 26,893 subjects were used. Columns 2 and 3 denote the negative logarithm of correlation p-value
(two-sided t-test) and Pearson’s correlation coefficient r.
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Structure − log10(p) r Imaging phenotype Non-imaging phenotype Field ID
LV
8.7 -0.04 Ecc AHA 15 Time to answer 4288-2.0
7.9 0.04 LVM Fluid intelligence score 20016-2.0
5.3 -0.04 Ell 3 Time elapsed 4256-2.1
5.0 -0.04 Ell 3 Interval between previous point and current one in alphanumeric path 6773-2.8
4.8 -0.04 Ell 3 Time last key touched 4255-2.1
RV
28.8 0.07 RVESV Fluid intelligence score 20016-2.0
7.1 -0.03 RVEDV Duration to first press of snap-button in each round 404-2.10
6.5 -0.03 RVEDV Mean time to correctly identify matches 20023-2.0
6.4 0.04 RVESV Number of puzzles correctly solved 6373-2.0
5.5 0.03 RVEDV FI3 : word interpolation 4957-2.0
LA
7.9 0.05 LAV min Interval between previous point and current one in alphanumeric path 6773-2.11
5.0 0.04 LAV min Interval between previous point and current one in numeric path 6772-2.21
4.7 0.04 LAV min Duration to complete alphanumeric path 6350-2.0
4.4 0.03 LAV min Duration to first press of snap-button in each round 404-2.7
4.3 0.03 LAV min Time elapsed 4256-2.2
RA
18.8 0.06 RAV max Fluid intelligence score 20016-2.0
6.1 0.04 RAV min Maximum digits remembered correctly 4282-2.0
5.7 0.04 RAV min Number of rounds of numeric memory test performed 4283-2.0
4.5 0.04 RAV max Value entered 6312-2.6
4.2 0.04 RAV max Number of puzzles correctly solved 6373-2.0
AAo
2.8 0.03 AAo max area Total errors traversing alphanumeric path 6351-2.0
2.5 0.03 AAo max area Interval between previous point and current one in alphanumeric path 6773-2.0
2.4 0.02 AAo max area Time to complete round 400-2.3
2.3 -0.03 AAo distensibility Duration to first press of snap-button in each round 404-0.3
2.2 0.02 AAo max area Time last key touched 4255-2.0
DAo
5.2 0.04 DAo min area Total errors traversing alphanumeric path 6351-2.0
5.0 -0.04 DAo min area Number of puzzles correctly solved 6373-2.0
3.3 -0.03 DAo min area Number of symbol digit matches made correctly 23324-2.0
3.3 0.03 DAo max area Interval between previous point and current one in alphanumeric path 6773-2.0
3.1 0.02 DAo min area Mean time to correctly identify matches 20023-0.0
Supplementary Table 13. Five most significant PheWAS associations in the cognitive function category for each
anatomical structure. n = 26,893 subjects were used. Columns 2 and 3 denote the negative logarithm of correlation p-value
(two-sided t-test) and Pearson’s correlation coefficient r.
LVM (g) LVEDV (mL) LVEF (%) RVEDV (mL) RVEF (%)
Birth weight, per 0.6 kg 0.5[0.3,0.7] (p=1.4×10−5) 1.0[0.6,1.5] (p=7.5×10−7) 0.1[−0.0,0.2] (p=0.090) 1.8[1.3,2.2] (p=7.4×10−15) -0.1[−0.2,−0.0] (p=0.013)
LAV max (mL) LAEF (%) RAV max (mL) RAEF (%)
Birth weight, per 0.6 kg -0.7[−1.0,−0.3] (p=4.3×10−4) 0.4[0.2,0.5] (p=2.5×10−6) 1.7[1.2,2.1] (p=2.2×10−14) 0.2[0.0,0.4] (p=0.011)
AAo max area (mm2) AAo distensibility DAo max area (mm2) DAo distensibility
Birth weight, per 0.6 kg 20.2[17.3,23.2] (p=10−40) -0.04[−0.1,−0.0] (p=8.8×10−4) 7.1[5.8,8.5] (p=3.2×10−26) -0.1[−0.1,−0.0] (p=5.5×10−4)
Supplementary Table 14. Associations of cardiac and aortic imaging phenotypes with birth weight. n = 12,169
subjects were used with available information for all independent variables. Sex, age, sex * age, weight, height, SBP, DBP,
current smoking status, alcohol intake, vigorous PA frequency, high cholesterol and diabetes were adjusted in regression. The
values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test p-value).
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LVM (g) LVEDV (mL) LVEF (%) RVEDV (mL) RVEF (%)
Risk taking 1.0[0.6,1.4] (p=4.4×10−6) 0.02[−0.8,0.8] (p=0.962) -0.3[−0.5,−0.1] (p=0.004) 0.2[−0.7,1.0] (p=0.724) -0.5[−0.7,−0.3] (p=1.6×10−7)
Neuroticism score, per 3.2 -0.03[−0.2,0.2] (p=0.744) -0.6[−0.9,−0.2] (p=0.002) 0.1[−0.0,0.2] (p=0.129) -1.0[−1.3,−0.6] (p=9.8×10−7) 0.1[0.0,0.2] (p=0.019)
LAV max (mL) LAEF (%) RAV max (mL) RAEF (%)
Risk taking -0.3[−1.0,0.5] (p=0.489) -0.5[−0.8,−0.2] (p=0.001) 0.8[−0.0,1.6] (p=0.063) -0.8[−1.1,−0.5] (p=5.3×10−7)
Neuroticism score, per 3.2 -0.4[−0.7,−0.1] (p=0.023) -0.04[−0.2,0.1] (p=0.585) -0.7[−1.0,−0.3] (p=3.7×10−4) 0.05[−0.1,0.2] (p=0.477)
AAo max area (mm2) AAo distensibility DAo max area (mm2) DAo distensibility
Risk taking 5.4[−0.3,11.1] (p=0.064) -0.01[−0.1,0.0] (p=0.553) 1.5[−1.0,4.1] (p=0.242) 0.02[−0.0,0.1] (p=0.462)
Neuroticism score, per 3.2 1.1[−1.4,3.7] (p=0.380) -0.01[−0.0,0.0] (p=0.391) -0.3[−1.5,0.8] (p=0.572) -0.01[−0.0,0.0] (p=0.658)
Supplementary Table 15. Associations of cardiac and aortic imaging phenotypes with mental health measures. n =
16,568 subjects were used with available information for all independent variables. Sex, age, sex * age, weight, height, SBP,
DBP, current smoking status, alcohol intake, vigorous PA frequency, high cholesterol and diabetes were adjusted in regression.
The values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test p-value). Risk taking is a binary
variable, with 0 denoting no and 1 denoting yes. Neuroticism score ranges from 0 to 12.
LVM (g) LVEDV (mL) LVEF (%) RVEDV (mL) RVEF (%)
Fluid intelligence, per 2.1 0.8[0.6,0.9] (p=1.8×10−18) 1.1[0.7,1.4] (p=3.3×10−10) -0.1[−0.2,−0.0] (p=0.033) 2.0[1.6,2.3] (p=2×10−26) -0.3[−0.3,−0.2] (p=3.9×10−10)
LAV max (mL) LAEF (%) RAV max (mL) RAEF (%)
Fluid intelligence, per 2.1 0.1[−0.2,0.4] (p=0.553) -0.01[−0.1,0.1] (p=0.879) 1.6[1.3,2.0] (p=1.9×10−20) -0.2[−0.3,−0.0] (p=0.013)
AAo max area (mm2) AAo distensibility DAo max area (mm2) DAo distensibility
Fluid intelligence, per 2.1 3.1[0.7,5.4] (p=0.012) -0.01[−0.0,0.0] (p=0.194) 0.7[−0.4,1.8] (p=0.208) 0.00[−0.0,0.0] (p=0.926)
Supplementary Table 16. Associations of cardiac and aortic imaging phenotypes with fluid intelligence score. n =
18,369 subjects were used with available information for all independent variables. Sex, age, sex * age, weight, height, SBP,
DBP, current smoking status, alcohol intake, vigorous PA frequency, high cholesterol and diabetes are adjusted in regression.
The values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test p-value). Fluid intelligence score
ranges from 0 to 13.
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SBP, per 18.0 mmHg 4.8[4.6,5.1] (p=10−324) 4.8[1.4,8.2] (p=0.006) 4.6[0.1,9.0] (p=0.044) 11.7[−1.5,24.9] (p=0.085)
Diabetes -1.0[−1.8,−0.1] (p=0.025) -0.3[−1.2,0.6] (p=0.499) -0.3[−1.3,0.7] (p=0.539) -0.02[−5.4,5.3] (p=0.995)
Birth weight, per 0.6 kg 0.5[0.3,0.7] (p=1.4×10−5) 1.2[0.5,1.9] (p=0.001) 1.0[0.0,2.1] (p=0.049) 1.8[−0.2,3.7] (p=0.078)
Risk taking 1.0[0.6,1.4] (p=4.4×10−6) 2.4[−1.5,6.3] (p=0.233) 3.8[−2.0,9.5] (p=0.196) 11.1[−5.3,27.5] (p=0.196)
Fluid intelligence, per 2.1 0.8[0.6,0.9] (p=1.8×10−18) 0.1[−1.1,1.4] (p=0.825) 0.2[−1.4,1.8] (p=0.820) -1.6[−7.3,4.2] (p=0.601)
LVEDV
(mL)
SBP, per 18.0 mmHg 5.8[5.3,6.3] (p=2.4×10−130) 0.8[−4.8,6.5] (p=0.771) -3.5[−11.0,3.9] (p=0.355) -5.5[−27.1,16.1] (p=0.617)
Diabetes -8.7[−10.3,−7.0] (p=1.4×10−24) -0.7[−2.1,0.8] (p=0.382) -0.9[−2.5,0.8] (p=0.311) -2.4[−11.3,6.5] (p=0.615)
Birth weight, per 0.6 kg 1.0[0.6,1.5] (p=7.5×10−7) 2.4[1.1,3.6] (p=1.5×10−4) 1.9[0.2,3.6] (p=0.031) 3.0[−0.3,6.4] (p=0.079)
Risk taking 0.02[−0.8,0.8] (p=0.962) 1.2[−5.5,7.9] (p=0.725) 3.8[−6.1,13.8] (p=0.452) 14.3[−13.9,42.6] (p=0.328)
Fluid intelligence, per 2.1 1.1[0.7,1.4] (p=3.3×10−10) 0.3[−1.8,2.4] (p=0.769) 0.3[−2.5,3.2] (p=0.816) -1.3[−11.2,8.6] (p=0.806)
LVEF
(%)
SBP, per 18.0 mmHg 0.9[0.8,1.0] (p=4.9×10−49) 0.2[−1.1,1.5] (p=0.757) 0.4[−1.3,2.1] (p=0.665) 2.6[−2.4,7.7] (p=0.309)
Diabetes -1.0[−1.4,−0.5] (p=5.1×10−6) -0.2[−0.5,0.1] (p=0.165) -0.3[−0.6,0.1] (p=0.116) -0.8[−2.3,0.7] (p=0.342)
Birth weight, per 0.6 kg 0.1[−0.0,0.2] (p=0.090) 0.2[−0.0,0.5] (p=0.080) 0.2[−0.2,0.6] (p=0.258) -0.1[−0.8,0.7] (p=0.863)
Risk taking -0.3[−0.5,−0.1] (p=0.004) 0.5[−1.3,2.2] (p=0.618) 0.4[−2.1,2.8] (p=0.773) 0.9[−6.7,8.4] (p=0.827)
Fluid intelligence, per 2.1 -0.1[−0.2,−0.0] (p=0.033) 0.2[−0.3,0.7] (p=0.364) 0.2[−0.5,0.8] (p=0.575) 1.3[−1.0,3.6] (p=0.288)
RVEDV
(mL)
SBP, per 18.0 mmHg 3.0[2.5,3.5] (p=4.8×10−32) 0.04[−5.8,5.9] (p=0.988) 0.4[−7.5,8.4] (p=0.916) 9.0[−13.6,31.5] (p=0.439)
Diabetes -11.1[−12.9,−9.3] (p=3.4×10−34) -1.6[−3.0,−0.3] (p=0.016) -1.8[−3.5,−0.1] (p=0.036) 2.3[−4.9,9.5] (p=0.549)
Birth weight, per 0.6 kg 1.8[1.3,2.2] (p=7.4×10−15) 3.2[1.8,4.5] (p=3.2×10−6) 2.8[1.0,4.6] (p=0.002) 4.3[0.6,7.9] (p=0.023)
Risk taking 0.2[−0.7,1.0] (p=0.724) 3.1[−4.3,10.6] (p=0.407) -0.5[−10.8,9.8] (p=0.919) 15.2[−16.2,46.5] (p=0.350)
Fluid intelligence, per 2.1 2.0[1.6,2.3] (p=2×10−26) 0.1[−2.0,2.3] (p=0.894) 0.4[−2.7,3.5] (p=0.811) -2.3[−12.9,8.2] (p=0.675)
RVEF
(%)
SBP, per 18.0 mmHg 1.6[1.5,1.7] (p=1.4×10−161) 0.9[−0.5,2.2] (p=0.222) -0.3[−2.0,1.4] (p=0.742) 0.4[−4.8,5.7] (p=0.877)
Diabetes -0.7[−1.1,−0.3] (p=5×10−4) -0.1[−0.5,0.2] (p=0.543) 0.04[−0.3,0.4] (p=0.850) -0.5[−2.7,1.6] (p=0.629)
Birth weight, per 0.6 kg -0.1[−0.2,−0.0] (p=0.013) -0.1[−0.4,0.2] (p=0.458) -0.1[−0.4,0.3] (p=0.790) -0.7[−1.5,0.1] (p=0.070)
Risk taking -0.5[−0.7,−0.3] (p=1.6×10−7) -0.1[−1.6,1.5] (p=0.946) 0.2[−2.1,2.5] (p=0.883) 0.1[−6.5,6.6] (p=0.979)





SBP, per 18.0 mmHg -13.5[−16.8,−10.2] (p=1.2×10−15) 32.3[−5.4,69.9] (p=0.093) 49.3[−4.4,103.0] (p=0.072) 60.3[−83.8,204.3] (p=0.415)
Diabetes -19.7[−31.5,−7.9] (p=0.001) -12.0[−20.0,−4.0] (p=0.003) -10.2[−20.5,0.1] (p=0.051) -19.1[−64.0,25.8] (p=0.429)
Birth weight, per 0.6 kg 20.2[17.3,23.2] (p=10−40) 25.1[16.0,34.2] (p=6.2×10−8) 19.5[7.6,31.5] (p=0.001) 14.9[−10.2,39.9] (p=0.246)
Risk taking 5.4[−0.3,11.1] (p=0.064) 15.2[−39.1,69.5] (p=0.582) 24.9[−48.4,98.2] (p=0.505) 152.2[−71.9,376.4] (p=0.194)




SBP, per 18.0 mmHg -0.2[−0.2,−0.2] (p=1.1×10−41) -0.3[−0.6,−0.0] (p=0.042) -0.4[−0.8,−0.0] (p=0.048) -1.0[−2.1,0.0] (p=0.062)
Diabetes 0.00[−0.1,0.1] (p=0.991) -0.1[−0.2,−0.0] (p=0.001) -0.1[−0.2,−0.0] (p=0.014) -0.2[−0.5,0.1] (p=0.297)
Birth weight, per 0.6 kg -0.04[−0.1,−0.0] (p=8.8×10−4) -0.03[−0.1,0.0] (p=0.269) 0.01[−0.1,0.1] (p=0.898) 0.1[−0.0,0.3] (p=0.058)
Risk taking -0.01[−0.1,0.0] (p=0.553) 0.1[−0.3,0.5] (p=0.591) -0.2[−0.7,0.3] (p=0.439) -0.00[−1.5,1.5] (p=0.995)
Fluid intelligence, per 2.1 -0.01[−0.0,0.0] (p=0.194) -0.1[−0.2,0.1] (p=0.449) -0.03[−0.2,0.1] (p=0.756) 0.2[−0.4,0.9] (p=0.490)
Supplementary Table 17. Effects of risk factors on cardiac and aortic imaging phenotypes by Mendelian
randomisation analysis, compared to observational analysis. n = 22,229 subjects were used with available genetic
information. For Mendelian randomisation, three methods were used, including inverse-variance weighting (IVW), weighted
median (WM) and MR-Egger. Sex, age, height and genetic principal components were adjusted. Observational analysis results
come from previously reported tables in this paper. The values are depicted as regression coefficient β [95% confidence
interval] (two-sided t-test p-value). The Bonferroni threshold for multiple comparison (5 risk factors and 7 imaging
phenotypes) is pBon f = 1.4×10−3 for α = 0.05.
29/30
Risk factor Data source Cohorts
SBP Evangelou et al, 201873 UK Biobank (n = 458,577) + ICBP (n = 299,024) + MVP (n = 220,520) + EGCUT (n = 28,742)
Diabetes Morris et al, 201274 DIAGRAM (n = 12,171 cases, n = 56,862 controls)
Birth weight Warrington et al, 201975 EGG (n = 80,745) + UK Biobank (n = 217,397)
Risk tolerance Linner et al, 201976 UK Biobank (n = 431,126) + 10 replication cohorts (n = 35,445)
Fluid intelligence Davies et al, 201177 CAGES (n = 3,511)
Supplementary Table 18. Data sources for the genetic associations of risk factors of interest. ICBP: International
Consortium of Blood Pressure Genome Wide Association Studies; MVP: Million Veteran Program; EGCUT, Estonian Genome
Center, University of Tartu; DIAGRAM: DIAbetes Genetics Replication and Meta-analysis; EGG: Early Growth Genetics;
CAGES: Cognitive Ageing Genetics in England and Scotland.
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